deoxycytidine has been researched along with Sarcoma in 107 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.80) | 18.2507 |
| 2000's | 40 (37.38) | 29.6817 |
| 2010's | 53 (49.53) | 24.3611 |
| 2020's | 11 (10.28) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, HY; Hu, C; Huang, ZD; Lin, LL; Liu, ZZ; Wei, RX | 1 |
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Alameda, M; Espinosa, E; Feliu, J; Gallego, A; Gutierrez-Sainz, L; Martinez-Fdez, S; Martinez-Marin, V; Martinez-Recio, S; Mendiola, M; Pedregosa-Barbas, J; Peña, J; Perez-Wert, P; Pertejo-Fernandez, A; Redondo, A; Villamayor, J; Viñal, D; Zamora, P | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Jones, RL | 1 |
| Hindi, N; Martin-Broto, J; Moura, DS | 1 |
| Adam, J; Assi, T; Baldi, GG; Barisella, M; Ben-Ami, E; Benjamin, RS; Blay, JY; Casali, PG; Czarnecka, AM; Desar, I; Duffaud, F; Dufresne, A; Fedenko, A; Ferraro, R; Frezza, AM; Gelderblom, H; Gounder, M; Gronchi, A; Hornick, JL; Jones, RL; Kawai, A; Le Cesne, A; Lo Vullo, S; Maki, RG; Mariani, L; Meurgey, A; Mir, O; Noguchi, E; Pantaleo, MA; Ravi, V; Sbaraglia, M; Schuetze, S; Siontis, B; Stacchiotti, S; Teterycz, P; Thornton, K; Vincenzi, B; Wagner, AJ; Yonemori, K | 1 |
| Chen, T; Choy, E; Cote, GM; Demetri, G; George, S; Marino-Enriquez, A; Merriam, P; Morgan, J; Nathenson, MJ; Thornton, K; Wagner, AJ | 1 |
| Cheng, J; Feldman, R; Fuks, Z; Fuller, J; Kolesnick, R; Owa, T; Tap, W | 1 |
| Li, P; Tian, Z; Wang, J; Wang, X; Yang, J; Yao, W; Zhang, F; Zhang, P | 1 |
| Abdelhamid, AH; Agarwal, S; Bobbili, PJ; Chugh, R; Demetri, GD; Duh, MS; Gounder, MM; Huynh, L; Lax, AK; Merriam, P; Patel, SR; Rajarethinam, A; Ratan, R; Thornton, M; Totev, TI; Van Tine, BA; Villalobos, VM; Whalen, J; Yang, J | 1 |
| Andrés, I; Arconada-Luque, E; Belandia, B; Bossi, G; Fernández-Aroca, DM; Garcia-Flores, N; Ortega-Muelas, M; Pascual-Serra, R; Roche, O; Ruiz-Hidalgo, MJ; Sabater, S; Sánchez-Prieto, R | 1 |
| Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A | 1 |
| Ahn, JH; An, H; Choi, Y; Kim, YH; Kim, YJ; Lee, J; Lim, HY; Lim, SH; Park, KH; Park, YS; Suh, DC; Yun, MS | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Allen, BG; Bradley, MD; Buettner, GR; Mapuskar, KA; Milhem, M; Monga, V; Schoenfeld, JD; Sibenaller, ZA; Spitz, DR; Wagner, BA | 1 |
| Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ | 1 |
| Anurova, O; Asano, N; Ben-Ami, E; Benjamin, RS; Blay, JY; Boye, K; Brahmi, M; Broto, JM; Brunello, A; Casali, PG; Collini, P; Dei Tos, AP; Desar, IME; Fedenko, A; Flucke, U; Frezza, AM; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Hornick, JL; Jones, RL; Kawai, A; Lo Vullo, S; Lobmaier, I; Lucibello, F; Mariani, L; Mir, O; Palmerini, E; Philippe, T; Picci, P; Ranchere, D; Ratan, R; Renne, SL; Rutkowski, P; Sbaraglia, M; Stacchiotti, S; Teterycz, P; Thway, K; Vincenzi, B; Wagner, AJ; Wagrodzki, M; Wang, WL; Yoshida, A | 1 |
| Al-Muderis, O; Antoniou, G; Benson, C; Constantinidou, A; Jones, RL; Messiou, C; Miah, A; Petruckevitch, A; Sebio, A; Thway, K; VAN DER Graaf, WT; Zaidi, S | 1 |
| Chawla, SP; Dry, SM; Eilber, FC; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Li, Y; Miwa, S; Miyake, K; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Tsuchiya, H; Wangsiricharoen, S; Yamamoto, N; Zhang, Z | 1 |
| Trent, JC; Van Tine, BA | 1 |
| Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Chan, PC; Chang, WY; Chen, CL; Kuo, WT; Lin, CY; Liu, RS; Shen, CC; Wang, HE; Wu, CY | 1 |
| Egerer, G; Ho, AD; Kosely, F; Schmier, JW; Schmitt, T; Wuchter, P | 1 |
| Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Eibl, H; Hahn, J; Hossann, M; Issels, RD; Lechner, K; Limmer, S; Lindner, LH; Schmidt, R; Wachholz, K; Zengerle, A | 1 |
| Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K | 1 |
| Andreou, D; Busemann, C; Ehninger, G; Gerdes, S; Pink, D; Reichardt, P; Richter, S; Schuler, MK; Tunn, PU | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| García del Muro, X; Martin-Liberal, J; Tirado, OM | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Kord Valeshabad, A; Mieler, WF; Setlur, V; Shahidi, M; Thomas, M | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Ballo, MT; Cormier, JN; Feig, BW; Hunt, KK; Lazar, AJ; Lewis, VO; Lin, PP; Patel, S; Pisters, PW; Pollock, RE; Thall, PF; To, CA; Tseng, WW; Zhou, S | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Mii, S; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S; Zhang, N; Zhang, Y; Zhao, M | 1 |
| Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Chang, J; Hong, X; Luo, Z; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, X | 1 |
| Cousin, S; Ducoulombier, A; Kotecki, N; Penel, N | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Anghinolfi, M; Casalini, AG; Gnetti, L; Majori, M | 1 |
| Chuman, H; Hatano, H; Hiraga, H; Hosaka, M; Iwamoto, Y; Joyama, S; Kaya, M; Kubo, T; Morioka, H; Nagano, A; Nishida, Y; Takahashi, M; Tanaka, K; Toguchida, J; Tsumura, H; Yoshikawa, H | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Allen-Auerbach, MS; Benz, MR; Chow, K; Czernin, J; Dry, SM; Eckardt, JJ; Eilber, FC; Elashoff, D; Evilevitch, V; Phelps, ME; Tap, WD; Weber, WA | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Hensley, ML | 1 |
| Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
| Dubreuil, P; Hermine, O; Humbert, M; Kow, K; Mansfield, CD; Moussy, A; Rose, B; Thamm, DH | 1 |
| Buesa, JM; Carrasco, JA; Casado, A; Cruz, J; Cubedo, R; de Andrés, R; De Juan, A; Fra, J; García-Del-Muro, X; Gómez-España, A; Laínez, N; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Meana, A; Pericay, C; Poveda, A; Rubió, J | 1 |
| Arias-Pulido, H; Bocklage, T; Cerilli, LA; Eberhardt, S; Lee, SJ; Movva, S; Muller, CY; Purdy, M; Quinn, R; Rabinowitz, I; Schmit, B; Snyder, D; Verschraegen, CF | 1 |
| Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY | 1 |
| Movva, S; Verschraegen, C | 1 |
| Alazraki, A; Brill, P; Clark, D; George, BA; Katzenstein, HM; Martin, M; Olson, TA; Qayed, M; Rapkin, L; Wasilewski-Masker, K | 1 |
| Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A | 1 |
| Issels, RD; Lindner, LH | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Eshun, F; Hingorani, P; Watanabe, M; White-Collins, A | 1 |
| Açikalin, M; Başeskioglu, B; Can, C; Duman, BB; Kara, IO; Yildirim, M | 1 |
| Buckner, JC; Edmonson, J; Frytak, S; Galanis, E; Mahoney, M; Okuno, S | 1 |
| Cognetti, F; Felici, A; Gelibter, A; Nardoni, C; Serrone, L | 1 |
| Patel, SR | 1 |
| Blum, RH; Edmonson, JH; Okuno, S; Priebat, DA; Ryan, LM | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
| Bauer, S; Schütte, J; Seeber, S | 1 |
| Danova, M; Imarisio, I; Natalizi, A; Porta, C; Riccardi, A; Sartore-Bianchi, A; Zimatore, M | 1 |
| Dutcher, JP; Garino, A; Larkin, M; Milowsky, MI; Nanus, DM | 1 |
| Buesa, JM; Díaz, A; Esteban, E; Fernández, A; Fra, J; López-Pousa, A; Losa, R; Sierra, M | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Argani, P; Brinker, DA; Haas, M; Montgomery, EA; Wu, J | 1 |
| Azemar, M; Bokemeyer, C; Hartmann, JT; Horger, M; Huober, J; Jakob, A; Kanz, L; Oechsle, K | 1 |
| Albritton, K; Anderson, PM; Dubansky, SA; Erlandson, L; Rodriguez, V; Trotz, B; Wiseman, GA | 1 |
| Bokhian, BIu; Lichinitzer, MR; Petrovichev, NN; Stepanova, EV | 1 |
| Folman, R; Khalid, T | 1 |
| Borden, EC; Karen, A; Mills, GM; Rankin, C; Von Burton, G; Zalupski, MM | 1 |
| Dumontet, C; Galmarini, CM; Jordheim, LP | 1 |
| Bay, JO; Blay, JY; Brain, E; Bui, NB; Cherix, S; Chevreau, C; Cioffi, A; Coindre, JM; Emile, G; Fayette, J; Isambert, N; Kwiatkowski, F; Le Cesne, A; Leyvraz, S; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Balañá, C; Buesa, JM; Casado, A; Esteban, E; Fra, J; García Del Muro, J; López-Pousa, A; Losa, R; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Sierra, M | 1 |
| Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E | 1 |
| Bains, MS; Carlson, DL; Halpern, NA; Hmidi, A; Maki, RG; Pastores, SM; Voigt, LP | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Demetri, GD; Desai, J; Dileo, P; George, S; Harmon, DC; Morgan, JA; Polson, K; Quigley, MT; Salesi, JM; Zahrieh, D | 1 |
| Azim, HA; Elsedewy, E | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Maki, RG | 1 |
| Bailly, C; Bay, JO; Cabrespine, A; Gilliot, O; Gimbergues, P; Mishellany, F; Vincent, C | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Cercato, MC; Ciccarese, M; Cognetti, F; Di Filippo, F; Ferraresi, V; Giannarelli, D; Nuzzo, C; Zeuli, M | 1 |
| Boven, E; Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
| Boven, E; Erkelens, CA; Hatty, SA; Pinedo, HM; Schipper, H | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
| Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E | 1 |
| Benjamin, RS; Burgess, MA; Gandhi, V; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Plunkett, W | 1 |
| Blay, JY; Hermans, C; Hogendoorn, PC; Judson, IR; Keizer, HJ; le Cesne, A; Nielsen, OS; Svancárová, L; van Glabbeke, M; van Hoesel, QG; van Oosterom, AT; Verweij, J | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
15 review(s) available for deoxycytidine and Sarcoma
| Article | Year |
|---|---|
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2013 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Osteosarcoma; Sarcoma | 2016 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2010 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
[Soft-tissue sarcoma: recent developments].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Gemcitabine in the treatment of soft tissue sarcomas.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cisplatin; Dendritic Cells, Follicular; Deoxycytidine; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
35 trial(s) available for deoxycytidine and Sarcoma
| Article | Year |
|---|---|
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Research Design; Sarcoma | 2020 |
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Indazoles; Middle Aged; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2013 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.
Topics: Adult; Bayes Theorem; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Extremities; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Sarcoma; Survival Analysis; Torso; Treatment Outcome | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vincristine; Young Adult | 2015 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Spain; Treatment Outcome; Young Adult | 2011 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult | 2012 |
Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Infant; Male; Neoplasm Grading; Recurrence; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Time Factors | 2012 |
Phase II trial of gemcitabine in advanced sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Survival Rate | 2002 |
Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Survival Rate; Treatment Outcome | 2003 |
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Sarcoma; Survival Rate; Therapeutics; Treatment Outcome | 2004 |
Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Sarcoma; Survival Analysis; Treatment Outcome | 2006 |
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; History, 16th Century; History, 17th Century; Humans; Male; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2008 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Safety; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukocytes, Mononuclear; Male; Middle Aged; Phosphates; Sarcoma; Soft Tissue Neoplasms | 2001 |
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Sarcoma; Survival Analysis | 2002 |
57 other study(ies) available for deoxycytidine and Sarcoma
| Article | Year |
|---|---|
m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Topics: Adenosine; Antineoplastic Agents; Deoxycytidine; DNA Copy Number Variations; DNA Methylation; Docetaxel; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Sarcoma | 2021 |
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2023 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Geriatric Assessment; Humans; Ifosfamide; Male; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Humans; Indazoles; Male; Middle Aged; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Tunica Intima | 2020 |
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Deoxycytidine; Endothelial Cells; Gemcitabine; Male; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sarcoma; Soft Tissue Neoplasms; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Topics: Adult; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Retrospective Studies; Sarcoma; Treatment Outcome | 2020 |
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Female; Gemcitabine; Health Records, Personal; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome; United States; Young Adult | 2021 |
p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase 11; Models, Theoretical; Radiation Tolerance; Sarcoma | 2021 |
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Taxoids; Young Adult | 2018 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Redox active metals and H
Topics: Animals; Antimetabolites, Antineoplastic; Ascorbic Acid; Cell Line, Tumor; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Hydrogen Peroxide; Iron; Mice, Nude; Oxidation-Reduction; Radiation-Sensitizing Agents; Sarcoma | 2018 |
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult | 2018 |
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Remission Induction; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2018 |
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Treatment Outcome | 2019 |
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Paclitaxel; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Topics: Deoxycytidine; Gemcitabine; Humans; Indazoles; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Evaluation of (131/123)I-5-iodo-2'-deoxycytidine as a novel proliferation probe in a tumor mouse model.
Topics: Animals; Bromodeoxycytidine; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Iodine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Tissue Distribution | 2013 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Gemcitabine; Half-Life; Hyperthermia, Induced; Liposomes; Male; Phosphatidylglycerols; Rats; Sarcoma | 2014 |
Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Prognosis; Sarcoma; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Staging; Neoplasms, Unknown Primary; Photoreceptor Cells, Vertebrate; Sarcoma; Taxoids; Tomography, Optical Coherence; Uveal Diseases; Vision Disorders; Visual Acuity | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Gemcitabine; Indazoles; Mice; Mice, Nude; Pyrimidines; Salmonella Infections; Salmonella typhimurium; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
Pulmonary metastases from low grade sarcoma in a patient with pulmonary sarcoidosis. Sarcoidosis or sarcoid-like reaction?
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Diagnosis, Differential; Drainage; Gemcitabine; Humans; Lung Neoplasms; Male; Multiple Pulmonary Nodules; Neoplasm Grading; Pleural Effusion, Malignant; Predictive Value of Tests; Sarcoidosis, Pulmonary; Sarcoma; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Gemcitabine; Humans; Japan; Middle Aged; Neutropenia; Osteosarcoma; Pneumonia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome; Tubulin Modulators; Young Adult | 2016 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Drug Synergism; Gemcitabine; Inhibitory Concentration 50; Piperidines; Protein Kinase Inhibitors; Pyridines; Sarcoma; Thiazoles; Vinblastine | 2012 |
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult | 2012 |
Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Sarcoma; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Early detection and gemcitabine/cisplatin combination positively effect survival in sarcomatoid carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Early Diagnosis; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2002 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Sarcoma | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Breast Neoplasms; Cytoplasmic Vesicles; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Microscopy, Electron, Transmission; Sarcoma; Soft Tissue Neoplasms; Transcription Factors; Treatment Outcome; Xanthomatosis | 2005 |
Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics, Non-Narcotic; Antigens, CD34; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Image Processing, Computer-Assisted; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Pain; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Remission Induction; Samarium; Sarcoma; Stem Cells; Time Factors | 2005 |
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Topics: Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sarcoma; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2005 |
Symptoms in cancer patients and an unusual tumor: Case 3. Follicular dendritic cell sarcoma.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Male; Prednisone; Sarcoma; Tomography, X-Ray Computed; Vinblastine; Vincristine; Vinorelbine | 2005 |
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA, Neoplasm; Drosophila melanogaster; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Phosphotransferases (Alcohol Group Acceptor); Sarcoma; Transfection | 2006 |
Management dilemmas due to a paratracheal follicular dendritic cell tumor.
Topics: Adult; Airway Obstruction; Antineoplastic Agents; Bronchoscopy; Dendritic Cells, Follicular; Deoxycytidine; Female; Gemcitabine; Humans; Radiotherapy; Respiration, Artificial; Sarcoma; Stents; Tracheal Neoplasms | 2006 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Squamous Cell; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1995 |
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |